secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001193125-25-174061
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena partner Novo Nordisk to advance coramitug to Phase 3 for ATTR-CM
-------------------------------------------------------------------------

- Novo Nordisk plans Phase 3 program for coramitug in ATTR-CM, start expected in 2025.
- Prothena eligible for up to $1.2B in milestones, $100M received to date.
- Clinical milestone payment triggered when prespecified enrollment criteria met in Phase 3.
- Coramitug is a potential first-in-class amyloid depleter antibody.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000119312525174061/0001193125-25-174061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000119312525174061/d42243d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-174061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer